ADO Antikörper
Kurzübersicht für ADO Antikörper (ABIN7241939)
Target
Alle ADO Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Produktmerkmale
- Polyclonal Antibody
-
Aufreinigung
- Affinity purification
-
Immunogen
- Synthetic peptide of human ADO
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- WB 1:1000-1:5000, IHC 1:25-1:100
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.3 mg/mL
-
Buffer
- PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
- ADO (2-Aminoethanethiol (Cysteamine) Dioxygenase (ADO))
-
Andere Bezeichnung
- ADO
-
Hintergrund
- Human thiol dioxygenases include cysteine dioxygenase (CDO, MIM 603943) and cysteamine (2-aminoethanethiol) dioxygenase (ADO, EC 1.13.11.19). CDO adds 2 oxygen atoms to free cysteine, whereas ADO adds 2 oxygen atoms to free cysteamine to form hypotaurine. Mouse Ado has strong and specific dioxygenase activity in vitro towards cysteamine but not cysteine. Recombinant Ado was shown to bind iron. Overexpression of Ado in HepG2/C3A cells increased the production of hypotaurine from cysteamine. Similar results were found with human ADO. When endogenous expression of ADO was reduced by RNA-mediated interference, hypotaurine production decreased. The demonstration of high levels of ADO in brain challenges the previous assumption that most of the taurine in the brain is a consequence of CDO activity.
-
Molekulargewicht
- 30 kDa
-
NCBI Accession
- NP_116193
-
UniProt
- Q96SZ5
Target
-